top of page
Phialogics' state-of-the-art platform transforms
native proteins into
powerful therapeutics
Phialogics is developing a pipeline of bi-functional, bi-specific, and multi-specific molecules to treat autoimmune diseases
Phialogics' state-of-the-art platform transforms
native proteins into
powerful therapeutics
Phialogics is developing a pipeline of bi-functional, bi-specific, and multi-specific molecules to treat autoimmune diseases
What clinicians are saying about us
"Phialogics’ unique immune-balance resetting approach has the potential to induce sustained remission for advanced diseases and in the future to be a preventive treatment for patients “at-risk” of autoimmune disease"
Paul Emery, member of SAB
Our unique First-in-Class immunomodulatory approach has a proof of concept in several translational in vivo models as well as in patient-derived materials ex vivo
Our unique First-in-Class immunomodulatory approach has a proof of concept in several translational in vivo models as well as in patient-derived materials ex vivo
Our Management Team
​Our Advisors
Our early investors
bottom of page